> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Axogen Lifts 2026 Revenue Outlook To At Least $290 Million After Third-Quarter Sales Climb 26.2%
- URL: https://www.bullished.co/axogen-lifts-2026-revenue-outlook-to-at-least-290-million-after-third-quarter-sales-climb-02735438/
- Published: 2026-10-28T11:24:46.000Z
- Updated: 2026-10-28T14:40:56.000Z
- Description: The nerve-repair company, now free of debt, also posted $350.1 million in cash and investments and closed its BioCircuit purchase.
- Author: Matteo Parrino
- Tags: Earnings, AXGN, Industry: Healthcare

[Axogen](https://www.bullished.co/tag/axgn/), which makes products surgeons use to repair damaged peripheral nerves, raised its full-year 2026 revenue forecast to [at least $290 million](https://www.sec.gov/Archives/edgar/data/0000805928/000080592826000106/ex991axgnearningsreleaseda.htm?ref=bullished.co), growth of at least 29%, after third-quarter sales rose 26.2%, according to an [8-K filed Wednesday](https://www.sec.gov/Archives/edgar/data/0000805928/000080592826000106/axgn-20261028.htm?ref=bullished.co). The guidance includes at least $7 million from BioCircuit, a company Axogen bought on October 1.

## Sales up, margin down a notch

Third-quarter revenue was [$75.8 million](https://www.globenewswire.com/news-release/2026/10/28/3390038/0/en/axogen-inc-reports-third-quarter-2026-financial-results.html?ref=bullished.co), against $60.1 million a year earlier. Gross margin slipped to 74.8% from 76.6%.

Net income was [$2.3 million](https://www.globenewswire.com/news-release/2026/10/28/3390038/0/en/axogen-inc-reports-third-quarter-2026-financial-results.html?ref=bullished.co), or $0.04 per share, compared with $0.7 million, or $0.01 per share, a year earlier. Adjusted EBITDA reached $13.4 million, up from $9.2 million.

For the first nine months, free cash flow was $18.9 million, versus negative $5.9 million in the same period of 2025\. Net income for the nine months was a loss of $18.8 million, which includes a $16.8 million loss on extinguishing debt.

CEO Michael Dale said growth across all markets "continues to validate our market development strategies."

## The guidance, with and without BioCircuit

Excluding BioCircuit, Axogen expects organic revenue of at least $283 million, growth of at least 26%. It continues to expect gross margin of at least 73% and positive free cash flow for the year.

The company said year-to-date growth was broad-based across extremities, oral maxillofacial and head and neck, and breast, driven by account productivity gains above 20%, a larger sales force and better commercial insurance coverage. Commercial payer coverage for its Avance nerve graft now reaches about 96% of covered lives in the U.S., after positive decisions from Elevance and Aetna.

## A debt-free balance sheet

Cash, restricted cash and investments stood at $350.1 million at September 30, up from $113.4 million at June 30\. Axogen closed an upsized public offering of 5,646,500 shares for $225 million in net proceeds; $200 million funded BioCircuit and $1.9 million covered transaction expenses. A company slide says it has no debt obligations.

Axogen's portfolio includes Avance Nerve Graft, a processed human nerve allograft, plus Axoguard nerve connectors and protectors. BioCircuit developed NerveTape, a coaptation aid the company says eliminates the need for micro-suturing.

Based on positive clinical study outcomes, Axogen decided to begin prostate market development in 2027.

Axogen will host a prostate-focused investor call and webcast on November 9 at 9:00 a.m. to lay out the clinical outcomes behind that decision.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Axogen, Inc. (AXGN)](https://www.sec.gov/Archives/edgar/data/0000805928/000080592826000106/axgn-20261028.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit ex991axgnearningsreleaseda.htm — Axogen, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000805928/000080592826000106/ex991axgnearningsreleaseda.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit axgn\_q3earningsreleasepr.htm — Axogen, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000805928/000080592826000106/axgn%5Fq3earningsreleasepr.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit q32026\_axgnxcorporatepre.htm — Axogen, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000805928/000080592826000106/q32026%5Faxgnxcorporatepre.htm?ref=bullished.co) — SEC EDGAR
- [Axogen, Inc. Reports Third Quarter 2026 Financial Results](https://www.globenewswire.com/news-release/2026/10/28/3390038/0/en/axogen-inc-reports-third-quarter-2026-financial-results.html?ref=bullished.co) — globenewswire.com

### More on Axogen

- [Axogen CFO Says $34 Million Nerve Tape Forecast Is Net Of Cannibalization](https://www.bullished.co/axogen-cfo-says-34-million-nerve-tape-forecast-is-net-of-cannibalization-541cd6e9/)
- [Axogen Will Start Prostate Nerve Repair Market Development In 2027, Citing Early Results From 220 Patients](https://www.bullished.co/axogen-will-start-prostate-nerve-repair-market-development-in-2027-citing-early-results-2c940db8/)

[All Axogen (AXGN) coverage →](https://www.bullished.co/tag/axgn/)